Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A great read from Michael J.Fox Foundation re:our grant:
Study Rationale:
In a previous MJFF-sponsored project, we evaluated PRE-084 (an experimental compound binding to the sigma-1 receptor) in pre-clinical models of Parkinson’s disease. Chronic treatment with PRE-084 produced a gradual improvement of motor deficits and activated molecules involved in brain repair. In this project, we will evaluate a sigma-1 receptor agonist (ANAVEX2-73) produced by Anavex, which is now being evaluated in patients with Alzheimer’s disease. In our experimental study, the efficacy of ANAVEX2-73 on Parkinson’s biology will be compared to that of PRE-084 and other Sig-1R ligands.
Hypothesis:
The overarching aims of the study are to find a dose of ANAVEX2-73 producing a pattern of neurorestorative effects comparable to that of PRE-084 and to translate this dose into an equivalent dose for human use.
Study Design:
We will test the biological activity of ANAVEX2-73 in pre-clinical models and compare to PRE-084, previously shown to promote recovery of forelimb use, up-regulation of trophic factors and anti-inflammatory effects in the brain in this model. We will assess target engagement by measuring the ability of the tested compounds to prevent a radioactive ligand from binding to brain sigma-1 receptors.
Impact on Diagnosis/Treatment of Parkinson’s Disease:
The present study holds potential to impact the way Parkinson’s disease is treated. We aim to develop a new pharmacological approach to boost repair mechanisms and dampen inflammation in the part of the brain that is most affected by Parkinson’s. If this treatment exerts the expected effects, it could slow the progression of the disease.
Next Steps for Development:
If successful, this study will accelerate the translation of pre-clinical findings into the first clinical trial of ANAVEX2-73 as a potential disease-modifying therapy for Parkinson’s disease. ANAVEX2-73 has already been tested for safety and tolerability in humans with positive results.
Hoping Missling will give a great pitch to listening welcome ears--we do have the goods--someone needs to be convinced !
Great read...thanks for posting...gives my confidence in the Science a boost
would be nice if they were interested in us !
I think it's taken way too long for things to develop here---did never imagine it would take this long !
agreed-to hell with the regulators--"we have this great Science that will benefit all these indications and we want the world to know about it"---why keep it hidden as they have been ?
basparks...glad to see we are on the same page re: the co.sprouting their wings a bit and letting the world know what they are all about--why all the hush hush secrecy? Are they ashamed of something?--they have such great,promising Science.Plant some seeds and get some positive publicity.You have to toot your own horn sometimes to get noticed.Nobody knows who we are--the co. needs to change this by communicating more effectively--sorry for rambling but getting very frustrated by the silence of the co. Shout it from the rooftops how great our science is !!!! The SP stuck here at $2.50 is a real shame!
I also e-mailed Dr.MacFarlane a couple of time awhile ago--he never did return an e-mail to me--I'm sure he has to be very careful what he discusses and with whom---hopefully you will get a response
the proof in "in the pudding"---the pudding is long over-due here---come'on good Dr. perform some magic !
don't consider myself a "whiner"--just have different expectations from management than you do--ever hear the expression "toot your own horn?"--sometimes management needs to "toot their own own"--let the investment community know what positive things are happening (when-if they are)
it doesn't bother you that the SP keeps drifting down-down-down ? And one of the reasons for this is the garbage communication policy of the co.
company communication with shareholders is extremely frustrating--Science may be good but investor relations very poor !
Will be interesting to see where it comes priced at--we shall soon see
AC Immune---Alzheimer's biotech to IPO---looking to value co. at $700million at high end of range---What say you good Dr.?
ipulator man---still on board?? vacation over? anything to add here ? when do we get data update ??
I know--just wishful thinking on my part that we would get some news !
maybe Avxl PR dept can answer this question !
No traction here--again--same old/same old-- when can we expect some news from this co?? been waiting !!!!!!!!!!
where do you get your figures? Schwab is currently showing 400k+ shares traded
I e-mailed the International Alzheimer's Conference asking if I could get a copy of a transcript for Dr.Gold's presentation--I received an e-mail in return saying no transcripts would be available--shucks !
Good move and kudo's for your efforts--hope your targets investigate and act !!
McMagyar...you sound like a real smart guy--I like your assessment of Anavex and 2-73. You need to get this info out to the investing public--Maybe you and the good DR should team up to let the world know how great the Science is (saying this tongue in cheek but halfway Meaning it) Someone (anyone) needs to spread the word !!!!!!!!!!!!!!!!!!!
well said Jonjones---the ship needs to be righted---going nowhere fast---great science and nothing to show for it !
Sept 12-13, Michael Gold, MD will be speaking at the 17TH INTERNATIONAL CONFERENCE ON ALZHEIMER’S DRUG DISCOVERY in Jersey. Any way we can find out what Dr.Gold discussed at the Conference??
Would sure be nice if he discussed the progress Anavex has been making in Australia !! Keep your fingers crossed !
Agree---news is very much needed here--waiting patiently---believe in the Science--now have to see the results ! Hope the good Dr. can deliver
Agree---not enough communication coming from the co.--need to keep the shareholders better informed !!!!!!!!!!!!!!
Can we expect to get 38 wk.data later this month? Comments? I'm hoping we do get an update !
basparks...what is Moa TIA
Powerful words from the Drs.--thanks for the reminders !!!!!!!!!!!
I doubt that (he will reply)
So what ever became of the piano player,painter, and golfer who regained their lost skills after taking 2-73?? This was headlines in the Australian press "Alzheimer's Breakthrough" just a few months ago. Was that all a hoax?? something made up? I don't understand how something this powerful can just disappear off the radar. Dr.MacFarlane was so enthused at that time saying how astonished he was from these happenings.Can these people be tracked(piano player etc) to see how they are doing now? Still responding positively??? Perplexed !!!!
Also a believer here but becoming discouraged--the Dr. needs to hold hands with the shareholders ( who support the co.) and give them some encouraging news and let them know WTF is going on !!!
shub....agree fully---need to get ph.3 for AD up and running--I believe Dr.MacFarlene stated ph3 should be running in early 2017--not that far off !!!!!!!!!!!
bourbon...welcome to the i hub board--glad to see you found your way here---now get the Dr. to get us some good news--we do need it to get this stock moving !!
make....good find-thanks for posting--I'll sleep a bit better tonight !!!!
I'm keeping my fingers crossed !!!!!!!!!!!!!!!!
Mc--with all these accomplishments why isn't the Market valueing this with a higher price PS ???????????
How positive are they on Anavex ?? Can you share ? Do they rate the stock a buy--strong buy??? TIA
Thank you---communication is key--keep the shareholders informed--other than ambiguous graphs-charts---when checking out the cos.pipeline at it's website it says WOW---yet please --where are we re: Epilepsy-Parkinson's-MS-Cancer-Rett- etc--some specifics please--and of course the data analysis on Alzheimer's is definitely way to slow in forthcoming--Dr--I hope you are reading this--we love and respect you but hey-come'on--you owe it to the shareholders---we are waiting !!!!!!!!!!!!!!!!!! INFO please !